Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02374814 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
A Phase 4 study of Rabies, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT02374814: Completed Phase 4 study of Rabies, sponsored by State University of New York - Upstate Medical University.
NCT02374814 is a Phase 4 study of Rabies that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02374814, a Phase 4 study of Rabies, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
Primary Outcome
Percentage of subjects achieving the protective titer of ≥ 0.5 IU/ml against rabies virus
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rabies vaccine
Study Locations (1)
New York
- State University of New York, Upstate Medical University (SUNY-UMU) - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-03-24 |
| Est. Completion | 2016-09-22 |
| Phase | Phase 4 |
What the finished NCT02374814 record still lists
NCT02374814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Rabies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02374814 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02374814 about?
NCT02374814 is a clinical study titled "Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis". The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
What is the current status of trial NCT02374814?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2015-03-24. Estimated completion is 2016-09-22.
What conditions does trial NCT02374814 study?
This clinical trial studies the following conditions: Rabies.
What interventions are being tested in trial NCT02374814?
The interventions under investigation include: Placebo (DRUG), Rabies vaccine (DRUG).
Who is sponsoring clinical trial NCT02374814?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02374814 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rabies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02374814's enrollment target sits among peer trials
60 1125th of 2000 higher than 800 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI